Vanguard Fiduciary Trust
SRPT icon

Vanguard Fiduciary Trust’s Sarepta Therapeutics SRPT Stock Holding History

Vanguard Fiduciary Trust’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Buy
698,313
+41,497
+6% +$785K ﹤0.01% 1688
2026
Q1 		$14.3M Buy
+656,816
New +$12.7M ﹤0.01% 1520

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Fiduciary Trust's SRPT Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Sarepta Therapeutics (SRPT) stake by 6.3% in Q2 2026, buying an estimated $785K and bringing the position to 698,313 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1688.

Vanguard Fiduciary Trust first reported a position in SRPT in Q1 2026 and has held it in 2 quarters since. The position peaked at $14.3M in Q1 2026. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Vanguard Fiduciary Trust held 698,313 shares of Sarepta Therapeutics worth $12.5M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 41,497 Sarepta Therapeutics shares in Q2 2026, an estimated $785K.
  • Sarepta Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1688 holding.
  • Vanguard Fiduciary Trust first reported a position in Sarepta Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Sarepta Therapeutics position peaked at $14.3M in Q1 2026.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.